The sales of antiarrhythmic medicines in Germany are projected to maintain stability between 2024 and 2028, with a value of 1 US Dollar PPP per capita in 2024 and a consistent value of 0.9 from 2025 through 2028. This indicates no significant year-on-year percentage variation, implying a steady demand. In 2023, the market likely saw similar figures, pointing to an absence of major short-term growth triggers. The compounded annual growth rate (CAGR) reflects consistency without marked changes.
Future trends to watch for include potential innovations in cardiac care that could influence demand, regulatory changes impacting medicine pricing, and demographic shifts such as an aging population which could increase the prevalence of arrhythmic conditions.
